Search PubMed⌕ Search

PubMed · 8489758

Contraception during lactation.

Abstract

The probability of pregnancy is very small during the first 2 months after delivery if the mother breast-feeds. The risk remains small for 6 months if the mother is fully breast-feeding her infant, is still amenorrhoeic and the child does not receive additional food. Under these conditions there is only about a 2% chance of pregnancy. Even full breast-feeding does not inhibit ovarian function after 6 months. Breast-feeding is a very important and efficient contraceptive method in the developing countries, but it is also a useful method in developed countries during the early puerperium. Barrier methods and progestogen-only hormonal methods (pills, implants and injectables) are the primary contraceptive alternatives during breast-feeding. They have no adverse effects on lactation, the condition of the infant or on maternal ovarian function. Sterilization is only a good alternative if the family wants a permanent method of contraception. Careful insertion of an IUD is possible even before the first menstrual period. Puerperal insertion of an IUD needs expertise and training because of the vulnerability of the very soft puerperal uterine wall. Combined oral contraceptives diminish milk production and therefore combined oral contraceptives are not recommended during lactation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Saarikoski. 1993. Contraception during lactation.. https://doi.org/10.3109/07853899309164165

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Psychogenic amenorrhea].

Any amenorrhoea noticed outside pregnancy, lactation and menopause periods might be of organic or functional origin. Today, non organic amenorrhoea are either called hypothalamic amenorrhoea, more exactly supra hypothalamic amenorrhoea; functional amenorrhoea--this definition being characterized by its lack of any anatomic substratum; or, psychogenic amenorrhoea--an etiologic definition. Like any amenorrhoea, functional or psychogenic amenorrhoea is the consequence of either anovulation or endometrial hypotrophy. Neuroendocrine sciences do open new exciting research perspectives but other ways all the more promising since hormonal mechanics would not be the explanation. Work on the unconscious is indeed the other road leading to these psychogenic amenorrhoea. The term "psychogenic"--of psychological origin--does not mean of unknown origin, provided we recognize the strong link between psyche and soma. Treatment for this kind of amenorrhoea is twofold: medical and psychotherapeutic. Even though psychological etiology is obvious, clinical examination must be rigorous and completed by complementary exams which will guide the therapeutics. This is reassuring to the patient for the gynaecologist she chose to consult is implied, and not the psychotherapist. This reassures us too, because what we care for, as doctors, is first of all the body. Psychotherapeutic support can be provided by the general practitioner or the gynaecologist, both with psychosomatics training, but a multidisciplinary approach must often be worked out.

Amenorrhea↗

Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.

Chemotherapy and ovarian ablation both independently improve survival in premenopausal women with hormone-sensitive breast cancer. Amenorrhea is a well-recognized occurrence after chemotherapy. The rate of chemotherapy-induced amenorrhea varies with patient age and chemotherapy regimens administered. However, the impact of chemotherapy-induced amenorrhea on prognosis is still being defined. Older studies in premenopausal women argue that the benefit with chemotherapy is a result of direct cytotoxicity alone. However, studies that restrict outcome analysis to hormone receptor-positive tumors suggest that chemotherapy has a dual mechanism in women with hormone-responsive tumors; indirect endocrine manipulation secondary to chemotherapy-induced ovarian suppression and direct cytotoxicity. The significant health ramifications involved with the induction of premature menopause as well as potential benefits necessitate a comprehensive evaluation of chemotherapy-induced amenorrhea. This review will discuss the incidence of amenorrhea with commonly-used adjuvant chemotherapeutic regimens, the possible benefits of chemotherapy-induced amenorrhea, and the challenges of interpreting the existing data in breast cancer trials.

Amenorrhea↗